Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?
Replimune Group (NASDAQ:REPL) shares fell 5.9% to $8.82, with trading volume down 91% from average levels. Analysts have mixed views, with HC Wainwright raising its price target to $22 and JPMorgan to $18, while the consensus rating remains "Buy" with an average target of $19.43. The company reported a quarterly EPS of ($0.82), missing estimates. Insiders have sold shares recently, and institutional investors hold 92.53% of the stock. Replimune focuses on developing oncolytic immunotherapies for cancer treatment.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) traded down 5.9% during trading on Friday . The company traded as low as $8.91 and last traded at $8.82. 86,686 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 931,113 shares. The stock had previously closed at $9.37.
Get Replimune Group alerts:
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $19.43.
Check Out Our Latest Analysis on REPL
Replimune Group Stock Down 6.8%
The stock has a market capitalization of $673.43 million, a PE ratio of -2.85 and a beta of 0.68. The company's fifty day moving average price is $8.42 and its 200-day moving average price is $11.11. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.25) EPS. Analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.
Insiders Place Their Bets
In other news, insider Konstantinos Xynos sold 7,952 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the sale, the insider now directly owns 146,933 shares in the company, valued at $1,184,279.98. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the sale, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 in the last ninety days. 8.80% of the stock is owned by company insiders.
Institutional Investors Weigh In On Replimune Group
Institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after buying an additional 1,083,633 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after purchasing an additional 124,344 shares during the period. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after purchasing an additional 237,185 shares during the period. Tang Capital Management LLC raised its stake in shares of Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP lifted its holdings in shares of Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after buying an additional 931,223 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.
Replimune Group Company Profile
(Get Free Report)Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Stories
- Five stocks we like better than Replimune Group
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Intel’s Turnaround May Be the Best Bet No One’s Watching
- Using the MarketBeat Dividend Yield Calculator
- 3 Defense Stocks That Will Profit From a Golden Dome
- What is a SEC Filing?
- ASML Stock Might Be the Safest Chip Play at This Price
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Replimune Group Right Now?
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
